Contrasting Presbia (OTCMKTS:LENSF) & InspireMD (NYSE:NSPR)

Presbia (OTCMKTS:LENSF) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Volatility & Risk

Presbia has a beta of 5.91, indicating that its stock price is 491% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Profitability

This table compares Presbia and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Presbia	N/A	N/A	N/A
InspireMD	-413.96%	-69.42%	-57.68%

Insider & Institutional Ownership

44.8% of InspireMD shares are held by institutional investors. 74.2% of Presbia shares are held by insiders. Comparatively, 34.1% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Presbia and InspireMD”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Presbia	N/A	N/A	N/A	N/A	N/A
InspireMD	$7.07 million	14.29	-$19.92 million	($0.83)	-2.92

Presbia has higher earnings, but lower revenue than InspireMD.

Analyst Recommendations

This is a breakdown of recent ratings for Presbia and InspireMD, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Presbia	0	0	0	0	0.00
InspireMD	0	0	2	0	3.00

InspireMD has a consensus target price of $4.50, indicating a potential upside of 85.95%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Presbia.

About Presbia

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.